Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | CA7 | P43166 | 1/20 | 0.49 |
| ▸ | CTSK | P43235 | 12/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | CTSS | P25774 | 4/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | CTSL | P07711 | 1/20 | 0.40 |
| ▸ | CTSB | P07858 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17951340 | 1.00 | CA1 (0.49) | CA1CA2CA7CTSKCYP2D6 | |
| SCHEMBL7515863 | 1.00 | CA1 (0.49) | CA1CA2CA7CTSKCYP2D6 | |
| SCHEMBL1128203 | 0.87 | CA1 (0.44) | CA1CA2CA7CTSKCYP2D6 | |
| SCHEMBL75827 | 0.84 | CTSK (0.53) | CA1CA2CA7CTSKCYP2D6 | |
| SCHEMBL73696 | 0.84 | CTSK (0.53) | CA1CA2CA7CTSKCYP2D6 | |
| SCHEMBL73697 | 0.84 | CTSK (0.53) | CA1CA2CA7CTSKCYP2D6 | |
| SCHEMBL7743860 | 0.84 | CTSK (0.49) | CA1CA2CA7CTSKCYP2D6 | |
| SCHEMBL27646611 | 0.82 | CA1 (0.49) | CA1CA2CA7CTSKCYP2D6 | |
| SCHEMBL27646608 | 0.82 | CA1 (0.49) | CA1CA2CA7CTSKCYP2D6 | |
| SCHEMBL27479498 | 0.82 | CA1 (0.49) | CA1CA2CA7CTSKCYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118638017-A | Preparation method and application of chiral 4-aminopentanol | 上海华默西医药科技有限公司 | 2024-09-13 | — | — | CN | disclosed |
| CN-116745292-A | Substituted pyridotriazine compounds and uses thereof | 吉利德科学公司 | 2023-09-12 | — | — | CN | disclosed |
| US-20170210765-A1 | PROCESS FOR PREPARING ALPHA-SILYLAMINE COMPOUNDS FROM ALPHA-SILYLMETHYL AZIDE COMPOUNDS | POSTECH ACADEMY-INDUSTRY FOUNDATION (KR) | 2017-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170210765-A1 | PROCESS FOR PREPARING ALPHA-SILYLAMINE COMPOUNDS FROM ALPHA-SILYLMETHYL AZIDE COMPOUNDS | ITGAL, MANBA, ITGA1 | CA1 1301/4885CA2 2831/4885CA7 1662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.